Quantifying the benefits and risks of psychostimulant medication for ADHD

Establishing the benefits and possible risks of psychostimulant medication as a treatment for childhood Attention Deficit Hyperactivity Disorder (ADHD) is vital, says Philip Shaw, M.D., Ph.D., a researcher with NHGRI's Social and Behavioral Research Branch. His review of a recent meta-analysis on the use of the psychostimulant methylphenidate for ADHD appeared in the Journal of the American Medical Association (JAMA) and is the subject of a
Source: NHGRI Homepage Highlights - Category: Genetics & Stem Cells Source Type: news